Open-label trial of imatinib mesylate in patients with refractory desmoplastic small round cell tumors (DSRCT) expressing PDGF-R [platelet derived growth factor receptor].
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2015
At a glance
- Drugs Imatinib (Primary)
- Indications Sarcoma
- Focus Therapeutic Use
- Sponsors Novartis
- 13 Apr 2010 Actual patient number (9) added as reported by ClinicalTrials.gov.
- 16 Feb 2010 Actual end date (June 2009) added as reported by ClinicalTrials.gov.
- 16 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.